Aug 2026· The Pediatric Infectious Disease Journal· 0 citations· 18 references
Medicine
TL;DR
Following nirsevimab introduction, pediatric ARI hospitalizations declined without evidence of viral replacement and the selective reduction in RSV coinfections suggests that RSV prevention may reduce infection complexity in addition to RSV-associated disease.
Abstract
Background
Nirsevimab prevents respiratory syncytial virus (RSV)-associated hospitalizations in infants. However, its impact on the broader epidemiology of acute respiratory infections (ARI) in hospitalized children remains unclear.
Methods
We conducted a retrospective study of ARI hospitalizations among children aged ≤5 years at a tertiary pediatric hospital in Parma, Emilia Romagna region, Italy, across 3 respiratory seasons (from September 1, 2022 to April 30, 2025), spanning the period before and after nirsevimab introduction (October 2024). All children hospitalized with ARI during the seasonal period (September-April) who tested positive for at least 1 respiratory virus by multiplex polymerase chain reaction were included. We analyzed temporal trends in ARI hospitalization rates, viral distribution and RSV-specific infection patterns. Hospitalization rates were contextualized using the resident population aged ≤5 years in Emilia Romagna.
Results
A total of 241 ARI hospitalizations were included, with 347 viral detections, of which 44.7% were monoinfections and 55.3% were coinfections. The incidence of ARI hospitalizations decreased in the 2024-2025 season compared with the previous 2 seasons (from 14.3 to 2.2 per 100 person-months). The overall distribution of respiratory viruses remained stable over time (P-trend = 0.4736), with RSV and rhinovirus accounting for approximately 35% and 30% of detections, respectively. The proportion of RSV monoinfections remained unchanged, whereas RSV coinfections declined significantly (P-trend = 0.0161).
Conclusions
Following nirsevimab introduction, pediatric ARI hospitalizations declined without evidence of viral replacement. The selective reduction in RSV coinfections suggests that RSV prevention may reduce infection complexity in addition to RSV-associated disease. Continued surveillance is needed to assess the long-term epidemiologic impact.
The introduction of universal prophylaxis with nirsevimab for all children in their first epidemic season has substantially reduced the burden of respiratory syncytial virus (RSV). However, a small number of breakthrough infections continue to occur despite immunization, mostly in previously healthy infants, and these...
A. Vittucci, L. Antilici, Alessandra Salvatori et al.· Viruses· 0 citations
ABSTRACT Background The COVID‐19 pandemic profoundly altered the circulation of respiratory viruses in children, changing the epidemiology of acute lower respiratory tract infections. In the postpandemic period, respiratory pathogens showed marked temporal variability. The 2024–2025 season was the first respiratory syn...
F. Attaianese, S. Campani, S. Trapani et al.· Influenza and Other Respirat...· 0 citations
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in infants and older adults worldwide. This retrospective study investigated the epidemiology and molecular characteristics of RSV in Taiwan from 2018 to 2024 using data from the National Community Virus Surveillance System, whic...
Su-Lin Yang, Ming-Tsan Liu, H. Huang et al.· PLoS ONE· 0 citations
The epidemiology of the analyzed viruses was consistent with worldwide surveillance trends and largely stable between the two later epidemic seasons, and in viral-bacterial association analysis the authors identified two significantly attracted pairs, in which virus is known to facilitate bacterial adherence to respira...
Denis E. Maslov, I. D. Osipov, D. S. Zabelina et al.· Frontiers in Pediatrics· 0 citations
Summary Background Acute viral bronchiolitis is the leading cause of hospitalisation in the first year of life, with Respiratory Syncytial Virus (RSV) accounting for more than 60% of cases. A long-acting monoclonal antibody (nirsevimab) has been introduced for infants entering their first epidemic season. 2024–2025 sea...
M. Spatuzzo, Antonio Corsello, M. Riccò et al.· The Lancet Regional Health -...· 1 citation· ⚡1
INTRODUCTION
Acute respiratory infections cause over 4 million deaths annually worldwide, half of which occur in children under 5 years, primarily in developing countries. This study investigated the impact of the coronavirus disease 2019 (COVID-19) pandemic on the epidemiological and clinical characteristics of pediat...
Ran Li, Hui Zhang, Chen-Kun Tan et al.· Journal of Infection in Deve...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.